Pepgen Inc (PEPG)

Apr 14, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - Bluefield Daily Telegraph

Apr 14, 2026

Apr 13, 2026

Biotech Firm PepGen Receives 'Moderate Buy' Rating from Analysts - National Today

Apr 13, 2026

Apr 12, 2026

PepGen: Modest FREEDOM2 Efficacy, Regulatory Overhang, and Competitive Pressures Underscore Sell Rating - TipRanks

Apr 12, 2026

Apr 11, 2026

Signal Recap: Should I set a stop loss on PepGen Inc2026 Pullback Review & Technical Confirmation Alerts - baoquankhu1.vn

Apr 11, 2026

Apr 10, 2026

PepGen crashes after mid-stage trial data for muscle disorder therapy - MSN

Apr 10, 2026

Apr 10, 2026

PepGen team joins Kansas City event to drive myotonic dystrophy research discussions - Traders Union

Apr 10, 2026

Apr 08, 2026

Rate Cut: Does PepGen Inc have declining or rising EPSAnalyst Upgrade & AI Powered Buy/Sell Recommendations - baoquankhu1.vn

Apr 08, 2026

Apr 08, 2026

PepGen joins MyotonicStrong conference to present clinical progress - Traders Union

Apr 08, 2026

Apr 08, 2026

Top 3 Health Care Stocks Which Could Blast Off This Quarter - Benzinga

Apr 08, 2026

Apr 07, 2026

Retail Trends: Is PepGen Inc forming a breakout pattern2026 Chart Watch & Long Hold Capital Preservation Tips - baoquankhu1.vn

Apr 07, 2026

Apr 06, 2026

Published on: 2026-04-07 21:04:49 - baoquankhu1.vn

Apr 06, 2026

Apr 06, 2026

PEPG.O Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 06, 2026

Apr 05, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Apr 05, 2026

Apr 04, 2026

PEPG Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026

Apr 04, 2026

PepGen stock plunges 26% on FDA partial clinical hold - Investing.com

Apr 04, 2026

Apr 03, 2026

PepGen Reports Encouraging Phase II FREEDOM2 DM1 Data at 5 mg/kg; 10 mg/kg Cohort Underway - National Today

Apr 03, 2026

Apr 02, 2026

Wedbush Maintains PepGen (PEPG) Outperform Recommendation - MSN

Apr 02, 2026

Apr 02, 2026

FDA places partial clinical hold on PepGen’s DM1 trial - Investing.com

Apr 02, 2026

Apr 02, 2026

Scholar Rock To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Sahm

Apr 02, 2026

Apr 01, 2026

Assay what? Eyes on Pepgen’s vim-sapping DM1 phase II - BioWorld MedTech

Apr 01, 2026

Apr 01, 2026

Buy Rating on PepGen: DM1 Program De-Risked by Stronger Underlying Biology and Upside from Higher-Dose Cohorts - TipRanks

Apr 01, 2026

Mar 31, 2026

PEPG: FREEDOM2's 5 mg/kg cohort showed promising safety and efficacy, supporting dose escalation - TradingView — Track All Markets

Mar 31, 2026

Mar 31, 2026

MACD Signal: What are the analyst revisions for NEOVIs PepGen Inc stock a good investment in YEAR2026 Volatility Report & Growth Focused Stock Reports - baoquankhu1.vn

Mar 31, 2026

Mar 31, 2026

PepGen Shares Fall After Data From Ongoing Phase 2 Study for Myotonic Dystrophy Type 1 Patients - MarketScreener

Mar 31, 2026

Mar 31, 2026

PepGen's 5 mg/kg Data Outlier: Is This a Prelude to a 10 mg/kg Comeback or Evidence of a Failed Strategy? - Bitget

Mar 31, 2026

Mar 31, 2026

PepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some Relief - Seeking Alpha

Mar 31, 2026

Mar 31, 2026

PepGen’s Stock Plummets Amid FDA Trial Hold and Market Reaction - StocksToTrade

Mar 31, 2026

Mar 31, 2026

PepGen (NASDAQ:PEPG) Price Target Lowered to $5.00 at Wedbush - MarketBeat

Mar 31, 2026

Mar 31, 2026

PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease - BioSpace

Mar 31, 2026

Mar 31, 2026

PepGen Inc. Shareholders Are Encouraged to Reach Out to - GlobeNewswire

Mar 31, 2026

Mar 31, 2026

A Quick Look at Today's Ratings for PepGen(PEPG.US), With a Forecast Between $3 to $20 - news.futunn.com

Mar 31, 2026

Mar 31, 2026

Why PEPG, SGMO, PHR are among top premarket losers today - MSN

Mar 31, 2026

Mar 31, 2026

Wedbush Cuts Price Target on PepGen to $5 From $9, Keeps Outperform Rating - marketscreener.com

Mar 31, 2026

Mar 31, 2026

Why Is PepGen Stock Sinking Tuesday? - Benzinga

Mar 31, 2026

Mar 31, 2026

PepGen posts trial data for muscle disorder drug (PEPG:NASDAQ) - Seeking Alpha

Mar 31, 2026

Mar 31, 2026

PepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT DataSlideshow (NASDAQ:PEPG) 2026-03-31 - Seeking Alpha

Mar 31, 2026

Mar 31, 2026

PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data - BioSpace

Mar 31, 2026

Mar 31, 2026

PepGen reports ‘promising’ topline results from MAD cohort - TipRanks

Mar 31, 2026

Mar 30, 2026

PepGen stock tumbles 44% on disappointing trial results By Investing.com - Investing.com Canada

Mar 30, 2026

Mar 30, 2026

Movement Recap: Should I set a stop loss on PepGen Inc2026 Breakouts & Short-Term Trading Alerts - baoquankhu1.vn

Mar 30, 2026

Mar 30, 2026

PepGen Reports Early Phase 2 FREEDOM2-DM1 Topline Data - TipRanks

Mar 30, 2026

Mar 30, 2026

PepGen reports mixed results from DM1 trial, 10mg cohort ongoing By Investing.com - Investing.com Australia

Mar 30, 2026

Mar 30, 2026

PepGen reports favorable safety and splicing trends for 5 mg/kg cohort, on track for 10 mg/kg readout - TradingView — Track All Markets

Mar 30, 2026

Mar 30, 2026

[8-K] PepGen Inc. Reports Material Event - Stock Titan

Mar 30, 2026